Apolipoprotein E1-Hammersmith (Lys146-->Asn;Arg147-->Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia

Atherosclerosis. 1996 Aug 2;124(2):183-9. doi: 10.1016/0021-9150(96)05819-4.

Abstract

Apolipoprotein E (apoE) is one of the major protein constituents of chylomicron and very low density lipoprotein (VLDL) remnants and plays a central role as a ligand in the receptor-mediated uptake of these particles by the liver. Here we describe a new variant of apoE, apoE1-Hammersmith, which is associated with dominantly expressed type III hyperlipidaemia. The propositus, aged 26, developed tubero-eruptive xanthomas at the age of 3, her daughter developed similar lesions at age 7 but her son, aged 3, shows no clinical abnormality so far. All three cases had an apoE3E1 phenotype and a broad beta band on lipoprotein electrophoresis. Cysteamine modification resulted in a shift of apoE1 to the apoE2 isoform position, indicating that the mutation leading to apoE1-Hammersmith occurred on an apoE3 background. ApoE genotyping confirmed these results. Sequence analysis of DNA of the propositus was performed for exons 3 and 4 and revealed a dinucleotide substitution causing two amino acid changes at adjacent positions (Lys146-->Asn) and (Arg147-->Trp).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticholesteremic Agents / therapeutic use
  • Apolipoproteins E / blood
  • Apolipoproteins E / drug effects
  • Apolipoproteins E / genetics*
  • Child
  • Child, Preschool
  • Cholesterol / blood
  • Cholestyramine Resin / therapeutic use
  • Cysteamine / therapeutic use
  • DNA / analysis
  • Dinucleotide Repeats / genetics*
  • Electrophoresis
  • Exons
  • Female
  • Fenofibrate / therapeutic use
  • Genotype
  • Humans
  • Hyperlipoproteinemia Type III / blood
  • Hyperlipoproteinemia Type III / drug therapy
  • Hyperlipoproteinemia Type III / genetics*
  • Hypolipidemic Agents / therapeutic use
  • Immunoblotting
  • Male
  • Nuclear Family
  • Phenotype
  • Point Mutation / genetics*
  • Radiation-Protective Agents / therapeutic use
  • Triglycerides / blood

Substances

  • Anticholesteremic Agents
  • Apolipoproteins E
  • Hypolipidemic Agents
  • Radiation-Protective Agents
  • Triglycerides
  • Cholestyramine Resin
  • Cysteamine
  • DNA
  • Cholesterol
  • Fenofibrate